Pluri vs Rallybio
Pluri reported revenue of $1 million in fiscal 2026, about the same as Rallybio's $1 million in fiscal 2025. Pluri's revenue fell 23.9% in its latest year, and Rallybio's grew 34.9%. Pluri had an operating margin of -2454.5%, against -3853.6% at Rallybio. Their fiscal years end in different months (June 30 and December 31), so the periods don't line up exactly.
Side by side
| Pluri | Rallybio | |
|---|---|---|
| Latest fiscal year | FY2026, Jun 30, 2026 | FY2025, Dec 31, 2025 |
| Revenue | $1M | $1M |
| Revenue growth | −23.9% | 34.9% |
| Revenue growth a year, last 5 years | — | — |
| Gross margin | 44.6% | — |
| Operating margin | −2,454.5% | −3,853.6% |
| Net margin | −2,344.6% | −1,046.4% |
| Free cash flow | −$20M | — |
| Free cash flow margin | −1,990.3% | — |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 53.8% | 3.4% |
| Last close | $0.97 | $15.52 |
| P/E at the last close | — | 3.4× |
| Insider trades, last 12 months | — | — |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
PluriRallybio
Operating margin
Percent of revenue
PluriRallybio
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
PluriRallybio